US Patent 9995733 Agents for treating disease
Patent 9995733 was granted and assigned to Biotest AG on June, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+327 characters)
Article
Patent abstract
Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof.
Edits on 1 Oct, 2023
Golden AI
Edits made to:
Infobox (+10 properties)
Infobox
Patent Inventor Names
André Engling0
Benjamin Daelken0
Chantal Zuber0
Christoph Bruecher0
Christoph Uherek0
Frank Osterroth0
Gregor Schulz0
Holger Wallmeier0
Kirsten Völp0
Niklas Czeloth0
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09995733 Agents for treating disease US Patent 9995733 Agents for treating disease
Infobox
Patent Number
099957330
Patent Number
99957330
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
099957330
Date of Patent
June 12, 2018
0Patent Application Number
134832800
Date Filed
May 30, 2012
0Patent Primary Examiner
Edits on 20 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 09995733 Agents for treating disease
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
09995733
Date of patent
June 12, 2018
Patent application number
13483280
Date Filed
May 30, 2012
Patent primary examiner
Find more entities like US Patent 9995733 Agents for treating disease
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.